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Abstract
Background: To diagnose multiple sclerosis (MS), evidence for dissemination in space and time is
required. There is no clear definition on how symptoms and signs of a patient indicate clinical
dissemination in space. To provide a uniform approach on this subject, a clinical classification system was
described recently differentiating patients with mono- and multifocal clinical presentation. Here we assess
the predictive value of clinically defined dissemination in space at first presentation for time to clinically
definite MS (CDMS).
Methods: Four hundred and sixty-eight patients with a first episode suggestive of MS were classified as
clinically mono- or multifocal by two neurologists blinded to magnetic resonance imaging (MRI) results.
These patients were part of the BENEFIT study in which 292 patients were randomized to interferon beta-
1b (IFNB-1b) and 176 to placebo. By using Kaplan-Meier statistics the risk for CDMS was studied in mono-
and multifocal patients of the placebo group, both with and without taking into account MRI measures of
potential prognostic relevance.
Results: Time to CDMS was similar in monofocal and multifocal patients. In monofocal patients, the risk
for CDMS over 2 years was significantly higher when ≥ 9 T2 lesions or at least one Gd-enhancing lesion
were present at the first event or 3 or 6 months after the first event. In patients with multifocal
presentation, these MRI measures had no significant added value in predicting time to CDMS.
Conclusion: These data indicate that a carefully performed neurological assessment of symptoms and
signs, combined with lesions on MRI, is important for defining the risk of conversion to CDMS.
Trial Registration: The Benefit trial has been registered under NCT00185211 http://
www.clinicaltrials.gov
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Background
Multiple sclerosis (MS) has a highly variable disease
course[1] and knowledge of factors that predict subse-
quent disease course in individual patients with a first
event suggestive of MS (also called patients with a clini-
cally isolated syndrome: CIS) is limited.
In CIS patients, magnetic resonance imaging (MRI) char-
acteristics have been described as a predictor of conver-
sion to clinically definite MS (CDMS) and of the
subsequent disease course. CIS patients with an abnormal
cerebral MRI scan at presentation have a substantially
higher long-term risk of conversion to CDMS than those
with a normal cerebral MRI[2]. Diagnostic guidelines for
MS include detailed MRI rules for the definition of dis-
semination in space of MS-specific pathology.[3,4] In
untreated[5] and treated[6] CIS patients fulfillment of
these criteria is associated with a high risk of CDMS.
According to the recommendations of the International
Panel (IP) on the Diagnosis of Multiple Sclerosis, disease
dissemination in CIS patients can also be identified by
clinical examination of symptoms and signs at the first
clinical event.[3] In contrast to a detailed algorithm on the
use of MRI criteria, however, it was left unclear how clini-
cal disease dissemination should be evaluated. Recently it
was shown that the clinical assessment of disease dissem-
ination can vary widely between physicians.[7] To stand-
ardize these assessments, a clinical classification system
was proposed.[7] This system was centrally applied to
patients of the BEtaferon®/BEtaseron® in Newly Emerging
multiple sclerosis For Initial Treatment (BENEFIT) study,
a study evaluating the impact of interferon beta-1b (IFNB-
1b) in CIS patients. By analyzing baseline data from this
study we have recently shown that patients with clinical
dissemination in space (multifocal, indicating more than
one clinical lesion) had more lesions on their MRI than
monofocal patients (those exhibiting symptoms and signs
from only one clinical lesion).[8]
In the present study we assessed the prognostic value of
this clinical classification system[7] for conversion to
CDMS and the added value of potentially prognostic MRI
parameters, by analyzing data obtained during the pla-
cebo-controlled treatment period of the BENEFIT study.
Methods
Study design, patients, and procedures
BENEFIT is a multicenter study comparing IFNB-1b to
placebo in CIS patients for up to 2 years, followed by a fol-
low-up period with IFNB-1b for up to 5 years after the CIS.
For the present analyses we used data from the placebo-
controlled first 2 years of the study. The design and main
outcomes of the placebo-controlled phase of the BENEFIT
trial have been reported elsewhere[9]. Patients completed
the placebo-controlled phase of BENEFIT if they either
reached 24 months of follow-up or were diagnosed with
CDMS. Briefly, inclusion criteria encompass: age between
18 and 45 years, presentation with a first neurological
event suggestive of MS, and the presence of at least two
clinically silent lesions on a T2-weighted brain MRI scan
with a minimum size of 3 mm, at least one of which was
ovoid, periventricular, or infratentorial.
Patients were randomly assigned in a 5:3 ratio to IFNB-1b
250 μg or placebo, by subcutaneous injection every other
day. Study treatment was initiated within 60 days of con-
firmation of the first clinical event. Regular visits were
scheduled for collection of clinical, MRI findings, and
other data on disability progression as measured by the
expanded disability status scale (EDSS)[10], All MRI scans
were performed with 0.1 mmol/kg gadolinium. MRI find-
ings and other parameters at months 3, 6, 9, 12, 18, and
24. Several MRI parameters were analyzed; in particular,
number of: gadolinium (Gd)-enhancing lesions, hyperin-
tense T2 lesions, hypointense T1 lesions, and newly active
lesions (NALs). A NAL was defined as a new T2 hyperin-
tense or Gd-enhancing lesion, or a newly enlarging T2
lesion. The numbers and volumes of hyperintense lesions
on T2-weighted images and Gd-enhancing lesions on T1-
weighted images were centrally evaluated at the Image
Analysis Center in Amsterdam, The Netherlands. MRI
analyses were performed by expert readers who were
blinded to the patients' clinical classification.
As MS according to the criteria proposed by the IP on the
Diagnosis of Multiple Sclerosis[3] was one of the primary
outcome measures, much emphasis was placed on the
clinical classification of patients. On the basis of all avail-
able information of clinical signs and symptoms, as doc-
umented by the local investigator, patients were classified
centrally by the consensus of two neurologists (CHP and
BMJU) as having an either monofocal or multifocal dis-
ease presentation according to the previously described
standardized scheme.[7] Briefly, on the basis of the neu-
rological symptoms the minimum number of central
nervous system (CNS) areas that could explain all symp-
toms was determined (= monofocal or multifocal presen-
tation as defined by symptoms). Subsequently, it was
decided whether abnormalities as revealed by the neuro-
logical examination (= signs) indicated the presence of
additional lesions in the CNS (= monofocal or multifocal
presentation as defined by signs).
In the case of a multifocal presentation it was then
decided whether the patient's multifocal classification was
purely based on multiple presenting symptoms (these
patients are denoted as multifocal patients by symptoms)
or whether clinical signs indicated additional CNS lesions
that did not correspond to any of the presenting symp-BMC Neurology 2009, 9:19 http://www.biomedcentral.com/1471-2377/9/19
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toms (these patients are denoted as multifocal patients by
signs). This subclassification of multifocal patients was
carried out under the hypothesis that such additional clin-
ical signs (in the absence of concomitant symptoms)
might point to subclinical disease activity preceding the
reported onset.
Statistical analysis
The following analyses were performed to evaluate differ-
ent disease characteristics of 1) monofocal versus multifo-
cal CIS patients; and 2) multifocal CIS patients by signs
only versus by symptoms only. In order to avoid any
influence of IFNB-1b treatment on the results, analyses on
time to CDMS were only performed in placebo patients
whilst analyses on baseline parameters were performed in
the total patient cohort. Analyses were performed using
SAS.
Comparison of key baseline characteristics between 
mono- and multifocal patients at the first event and 
between the multifocal subgroups by signs and by 
symptoms (all patients)
The following parameters were analyzed: Age, sex, steroid
use at first event, EDSS at screening, positive CSF findings,
number of T2-hyperintense lesions, number of/propor-
tion of subjects with at least one Gd-enhancing lesion(s),
proportion of subjects with at least one T1 hypointense
lesion.
Comparison of time to CDMS and MRI disease activity 
between the monofocal and multifocal patients and 
between the multifocal subgroups by signs and by 
symptoms (placebo patients)
Time to CDMS was analyzed as a measure for clinical
activity and the annualized cumulative number of NALs
over the study was analyzed as a measure of subclinical
activity.
Comparison of the impact of MRI findings at screening, 
month 3, and month 6 on time to CDMS within the 
monofocal and multifocal group separately (placebo 
patients)
These analyses were only performed on data from the
mono- and multifocal subgroups, as patient numbers
were too small to further stratify the multifocal subgroups
by symptoms and by signs. The following MRI parameters
were evaluated: presence of Gd-enhancement, or pro-
nounced disease dissemination (≥ 9 T2 lesions) on the
screening MRI; new Gd-enhancement at months 3 or 6.
Dichotomous variables were compared using Fisher's
exact test. Continuous variables were compared using the
Mann-Whitney U-test (comparison of the cumulative
number of NALs was done by a Wilcoxon test). Kaplan-
Meier survival analysis was used to analyze time to CDMS.
Group comparisons for this outcome measure were per-
formed using the log-rank test. Interaction of clinical
mono-/multifocality and MRI parameters was analyzed
by Cox proportional hazards regression. Reported p-val-
ues are based on two-tailed significance tests, with the
threshold for significance set at 0.05. Analyses were per-
formed post hoc on data from the placebo-controlled
period of the BENEFIT study for all patients who were ran-
domized and received study medication at least once.
Results
Four hundred and eighty-seven patients were randomized
and 468 started treatment in the BENEFIT study. Four
hundred and thirty-seven of these (93.6%) completed the
placebo-controlled study. Two hundred and ninety-two
patients received IFNB-1b and 176 received placebo. The
main outcome data have previously been published[9].
Comparison of key baseline characteristics of mono- and 
multifocal CIS patients (all patients)
Two hundred and forty-six (53%) patients were classified
as monofocal and 222 (47%) as multifocal. Baseline char-
acteristics of mono- and multifocal patients are outlined
in Table 1 and have been reported previously[8]. In sum-
mary: Multifocal patients had a higher number of T2-
hyperintense lesions (p = 0.018) and more frequent T1-
hypointense lesions (p = 0.030).
Comparison of time to CDMS and MRI disease activity 
between the monofocal and multifocal patients (placebo 
patients)
Neither time to CDMS (Hazard ratio/± 95% CI: 1.09/
0.70–1.71; p = 0.71) nor the annualized cumulative
number of NALs (p = 0.47 by Wilcoxon test and p = 0.51
by baseline adjusted non-parametric ANCOVA, see Table
2) differed significantly between mono- and multifocal
placebo patients.
Comparison of the impact of MRI findings at screening, 
month 3, and month 6 on time to CDMS within the 
monofocal and multifocal group separately (placebo 
patients)
The risk of CDMS was significantly higher in monofocal
placebo patients with ≥ 9 T2-hyperintense lesions at
screening (Hazard ratio/± 95% CI: 2.13/1.05–4.34; p =
0.032), with at least one Gd-enhancing lesion at screening
(Hazard ratio/± 95% CI: 2.28/1.24–4.18; p = 0.006), with
at least one Gd-enhancing lesion at month 3 (Hazard
ratio/± 95% CI: 3.03/1.51–6.07; p < 0.002), and with at
least one Gd-enhancing lesion at month 6 (Hazard ratio/
± 95% CI: 3.98/1.84–8.65; p < 0.001) than in monofocal
placebo patients without these criteria (Figure 1, 2).
The risk of CDMS was not significantly higher in multifo-
cal placebo patients with ≥ 9 T2-hyperintense lesions atBMC Neurology 2009, 9:19 http://www.biomedcentral.com/1471-2377/9/19
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screening (Hazard ratio/± 95% CI: 0.74/0.36–1.54; p =
0.42), with at least one Gd-enhancing lesion at screening
(Hazard ratio/± 95% CI: 0.96/0.48–1.93; p = 0.92), with
at least one Gd-enhancing lesion at month 3 (Hazard
ratio/± 95% CI:1.03/0.48–2.23; p = 0.94), and with at
least one Gd-enhancing lesion at month 6 (Hazard ratio/
± 95% CI: 2.04/0.86–4.86; p = 0.11), than in multifocal
placebo patients without these criteria (Figure 1, 2).
This differential effect of MRI parameters on the risk of
conversion to CDMS in these two patient groups (mono-
focal and multifocal) was confirmed by Cox proportional
hazards regression. This analysis revealed a significant
interaction between mono-/multifocality and either ≥ 9
T2-hyperintense lesions at screening (Hazard ratio/± 95%
CI: 0.35/0.13–0.96; p = 0.042) or at least one Gd-enhanc-
ing lesion at month 3 (Hazard ratio/± 95% CI: 0.34/0.12–
0.96; p = 0.042), but not between mono/multifocality
and at least one Gd-enhancing lesion at screening (Hazard
Table 1: Disease characteristics of monofocal vs multifocal CIS patients
All Monofocal Multifocal p-value*
N 468 (100%) 246 (53%) 222 (47%)
Sex – % of females 71% 66% 76% 0.0325†
Age, median
(quartiles)
30
(24–37)
29
(24–37)
31
(25–37)
0.0820‡
Steroid treatment – % 71% 72% 70% 0.6835†
EDSS (screening), median (quartiles) 2
(1–2.5)
1.5
(1–2)
2
(1.5–2.5)
< 0.0001‡
CSF positive of samples taken – % 267/314
85% (57%)
149/176
85% (61%)
118/138
86% (53%)
0.8745†
Number of T2 lesions, median (quartiles) 17
(7–38)
16
(6–36)
21
(8–41)
0.0182‡
At least one Gd-enhancing lesion – % 42% 42% 43% 0.9254†
At least one T1 hypointense lesion – % 68% 63% 73% 0.0300†
*Compares monofocal vs. multifocal patients. P-value in bold when p ≤ 0.05
†Fisher's exact test
‡Mann-Whitney U-test
EDSS: expanded disability status scale
CSF: cerebrospinal fluid
Gd: gadolinium
Table 2: Disease course of monofocal vs. multifocal placebo patients after the CIS
All Monofocal Multifocal p-value*
N 176 93 83
CDMS %* over 2 years 45% 47% 44% 0.7052†
Median annualized cumulative number of NALs over the study (quartiles) 3.2
(0.96–10.4)
3.0
(0.5–9.4)
3.6
(1.0–12.5)
0.4698‡
*Compares monofocal vs. multifocal patients
NAL: newly active lesion
CDMS: clinically definite MS
† Kaplan-Meier estimate at day 720, Log rank test
‡Wilcoxon testBMC Neurology 2009, 9:19 http://www.biomedcentral.com/1471-2377/9/19
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ratio/± 95% CI: 0.42/0.17–1.05; p = 0.064) or at least one
Gd-enhancing lesion at month 6 (Hazard ratio/± 95% CI:
0.50/0.16–1.6; p = 0.246).
Comparison of key baseline characteristics of multifocal 
patients by symptoms and multifocal patients by signs at 
the first event (all patients)
One hundred and twenty-two (55%) of the 222 multifo-
cal patients presented by symptoms, while 100 (45%)
presented by signs (the classification of these latter
patients was based on the presence of signs indicating an
additional clinical lesion, according to the central classifi-
cation). Baseline characteristics did not differ significantly
between multifocal patients by symptoms and by signs
(Table 3).
Comparison of time to CDMS and MRI disease activity 
between multifocal patients by symptoms and by signs 
(placebo patients)
There was no statistically significant difference between
the survival curves of "Time to CDMS" comparing multi-
focal placebo patients by symptoms and by signs (Hazard
ratio/± 95% CI: 0.72/0.36–1.45; p = 0.36). Multifocal pla-
cebo patients by symptoms developed a higher annual-
ized number of NALs over the study period (p = 0.042 by
Wilcoxon test; Table 4, supplemental data file).
Time to CDMS in mono- vs multifocal placebo patients stratified by MRI findings at screening Figure 1
Time to CDMS in mono- vs multifocal placebo patients stratified by MRI findings at screening. Note the predic-
tive value of baseline MRI findings in monofocal patients (left panels) and the absence of predictive value of MRI in multifocal 
patients (right panels). There was a significant interaction between mono-/multifocality and the presence of either ≥ 9 T2 
hyperintense lesions (p = 0.042). CDMS: clinically definite MS.BMC Neurology 2009, 9:19 http://www.biomedcentral.com/1471-2377/9/19
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Discussion
In a cross-sectional analysis of baseline data from CIS
patients in the BENEFIT study we have recently demon-
strated that clinical dissemination of the disease corre-
sponds to more widespread subclinical CNS pathology as
detected by cerebral MRI[8]. In the present study we
addressed whether clinical disease dissemination in these
patients also indicates an increased risk for subsequent
disease activity, and whether the presence versus absence
of clinical dissemination has an impact on the prognostic
value of MRI parameters.
Patients with monofocal versus multifocal clinical presen-
tation did not differ in terms of their risk for CDMS or
with respect to the annualized number of NALs over the
2-year placebo-controlled period, as has been reported
previously [11]. However, we did find that MRI findings
of subclinical disease dissemination or activity have a dif-
ferent prognostic value for development of CDMS in
mono- versus multifocal CIS patients. The presence of at
least nine T2 lesions or at least one Gd-enhancing lesion
during screening was predictive for time to CDMS in
monofocal patients though not in multifocal patients.
Similar observations were made for the prognostic value
of a new Gd-enhancing lesion on an MRI scan performed
Time to CDMS in mono- vs multifocal placebo patients stratified by MRI findings at month 3 and month 6 Figure 2
Time to CDMS in mono- vs multifocal placebo patients stratified by MRI findings at month 3 and month 6. 
Note the significant predictive value of months 3 and 6 MRI findings in monofocal patients (left panels) and the absence of pre-
dictive value in multifocal patients (right panels). There was a significant interaction between mono-/multifocality and the pres-
ence of at least one Gd-enhancing lesion at month 3 (both p = 0.042). CDMS: clinically definite MS.BMC Neurology 2009, 9:19 http://www.biomedcentral.com/1471-2377/9/19
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at month 3 or month 6. Thus, in monofocal, but not in
multifocal patients the risk for CDMS depends on MRI
findings. This differential impact of MRI findings in CIS
patients with clinical monofocal versus clinical multifocal
presentation was supported by a significant interaction
between the impact of clinical mono-/multifocality and ≥
9 T2 lesions at baseline and at least one Gd-enhancing
lesion at month 3 on time to CDMS.
These findings strongly suggest that only in CIS patients
with monofocal clinical presentation do MRI findings
have prognostic value. We hypothesize that, whilst in
monofocal CIS patients more pronounced subclinical dis-
ease dissemination might primarily reflect more active
disease, similar findings in multifocal patients may be
more indicative of prolonged subclinical disease evolu-
tion, and as such MRI adds less information in these
patients.
To further elaborate on this hypothesis we expanded these
comparisons to subgroups of multifocal patients: those by
symptoms and those by signs, under the assumption that
especially those patients multifocal by signs may have had
an earlier event that was asymptomatic or forgotten, and
Table 3: Disease characteristics of multifocal patients by symptoms and by signs at the CIS
Multifocal Multifocal by symptoms Multifocal by signs p-value
N 222 122 100
Sex – % of females 76% 77% 74% 0.6389†
Age, median
(quartiles)
31
(25–37)
30.5
(25–36)
31
(25–38)
0.7919‡
Steroid treatment – % 70% 72% 67% 0.4632†
EDSS (screening), median (quartiles) 2
1.5–2.5
2
1.5–2.5
2
1.5–2.5
0.9598‡
CSF positive of samples taken – % 118/138
86% (53%)
62/70
89% (51%)
56/68
82% (56%)
0.3405†
Number of T2 lesions, median (quartiles) 21
(8–41)
19.5
(8–47)
22.5
(9–40)
0.9130‡
At least one Gd-enhancing lesion – % 42% 45% 39% 0.3376†
At least one T1 hypointense lesion – % 73% 71% 74% 0.7627†
†Fisher's exact test
‡Mann-Whitney U-test
EDSS: expanded disability status scale
CSF: cerebrospinal fluid
Gd: gadolinium
Table 4: Disease course of multifocal placebo patients by symptoms and by signs after the CIS
All multifocal Multifocal by symptoms Multifocal by signs p-value*
N 83 50 (60%) 33 (40%)
CDMS %* over 2 years 44% 49% 37% 0.3554†
Median annualized cumulative number of NALs over the study (quartiles) 3.6
(1.0–12.5)
5.3
(1.6–13.4)
2.6
(0–7.0)
0.0424‡
*Compares multifocal patients by symptoms vs. multifocal patients by signs
†Kaplan-Meier estimate at day 720, Log rank test
‡Wilcoxon test
CDMS: clinically definite MS
NAL: newly active lesion
Gd: gadoliniumBMC Neurology 2009, 9:19 http://www.biomedcentral.com/1471-2377/9/19
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therefore may have a longer and more benign form of the
disease. We found similar baseline characteristics and
only a nonsignificant difference in time to CDMS in these
subgroups. The observation that multifocal placebo
patients by symptoms tended to have more active MRI
lesions during the study than multifocal placebo patients
by signs further supports our hypothesis that the former
may be considered more acute and at higher risk for future
disease activity than a multifocal patient by signs in whom
a longer subclinical disease history might be assumed.
Differences with respect to patients showing at least one
Gd-enhancing lesion (more in patients multifocal by
symptoms) and patients showing at least one T1-hypoin-
tense lesion (more in patients multifocal by signs) as
shown in Table 3, although not significant, are also sup-
portive of our hypothesis.
We compared our results to those obtained in the Early
Treatment of MS (ETOMS)[12] and Controlled High-Risk
Avonex®  Multiple Sclerosis Prevention Study
(CHAMPS)[13] studies, other interventional trials in CIS
patients where comparable analyses were performed. In
the ETOMS study, the presence of three or more MRI cri-
teria as incorporated in the International Panel on the
Diagnosis of Multiple Sclerosis guidelines[3] was also pre-
dictive for CDMS only in patients who were classified as
clinically unifocal[6]. Unlike our observation, multifocal
patients in ETOMS had a higher risk for CDMS. This dif-
ference in the predictive value of "multifocality" in the
BENEFIT and the ETOMS cohort may result from the dif-
ferent methods used to classify patients in the two studies.
Evaluation of clinical dissemination in ETOMS was based
on the local investigator's assessment, whilst multifocality
in BENEFIT was based on a central assessment procedure
according to a proposed classification system of all pre-
senting clinical symptoms and signs. Thus, multifocality
in BENEFIT was also assumed in patients who, in addition
to a monosymptomatic presentation [e.g. optic neuritis],
presented with additional clinical signs (e.g. pyramidal
dysfunction as indicated by extensor plantar response)
indicating an additional clinical lesion. Also, in a post hoc
analysis of the CHAMPS study[14] all patients were reclas-
sified, taking into account the results of neurological
examinations at baseline. In a multivariate analysis, clas-
sification by focality was not predictive of conversion to
CDMS, which is in line with our results.
All patients in BENEFIT, ETOMS, and CHAMPS had a
minimum number of asymptomatic T2 lesions; therefore
it is unclear whether these results also can be applied to
CIS patients with fewer or no lesions. Further limitations
of our analyses should be considered. All subgroup anal-
yses were performed post hoc and our results need confir-
mation, particularly the novel findings in the subgroups
of multifocal CIS patients. However, we would like to
emphasize the similarities between our findings and the
ETOMS study[6] in terms of the lack of impact of MRI
findings in multifocal patients on the risk of CDMS.
Conclusion
To summarize, MRI lesions may generally be interpreted
as indicators of past and future disease activity in patients
with monofocal presentation, though not in multifocal
patients, in whom their presence does not add to the risk
as defined by the clinical evaluation only. Our findings
show that a carefully performed neurological assessment
of symptoms and signs in CIS patients is important to
define the risk of conversion to CDMS and the potential
added value of MRI investigations.
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